So they'll receive 2mil up front on the Swedish Orphan International AB deal, and Swedish Orphan International will pay Viragen for Multiferon® at an agreed upon sales price, and, in addition, Viragen will receive double-digit royalties from Swedish Orphan International on their net sales.
Then a licensing agreement with Orphan Australia Proprietary Limited that grants exclusive rights to Orphan Australia to market, stated back in Dec of 06, estimated the agreement to be valued at approximately $10 - 15 million (USD) per year for us.
Is that correct? Seems things are going better than what the market realizes at this time.
Temp
